Be Wary of the Techno-Fix
By Marcy Darnovsky,
Boston Review
| 11. 19. 2018
In Merve Emre’s essay "All Reproduction is Assisted," her commitment to the emancipatory power of reproductive technologies is untroubled by her own accounts of unsatisfactory endings. Perhaps she assumes that one day soon, when the technologies improve, they will set us free.
In her essay, Merve Emre declares that “all reproduction . . . is assisted.” Few feminists of any wave or stripe would disagree. But if the statement that none of us go it alone is solid, some of Emre’s other moves put her on shaky ground. In her opening volleys, she skips lightly across fifty years of feminist thinking about reproductive technologies, leaping from Shulamith Firestone to Adrienne Rich to xenofeminism, with a brief stop at Donna Haraway’s “A Cyborg Manifesto” (1984). She arrives at a diagnosis of contemporary reproductive culture: it is infected, she says, by “the discourse of the natural.” She takes contemporary feminism to task for this state of affairs, suggesting that it has not been sufficiently enthusiastic about high-tech reproduction and asserting that it “has not done a good enough job articulating what alternate strategies of reproduction may be.”
Is that really a fair critique of feminism today? Most feminists have long been aware that simplistic appeals to nature can justify anything, including gender inequalities and oppression. And while questions about “nature” and “technology” are very...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...